COMPANY PROFILE
Pharmact Holding AG – Innovation, Expansion, Market Penetration. With our proprietary enzyme D016, which combines the mechanisms of established hyaluronidases, we are ideally positioned to serve the market for cardiovascular and neurodegenerative diseases on a large scale.
The subsidiaries of Pharmact Holding ensure production, development, and distribution – from research to the patient.
Our solid patent strategy, combined with expertise in manufacturing and marketing, offers investors the opportunity to create sustainable value in a forward-looking healthcare sector.
Based in Saarlouis, Germany, Pharmact Pharmaceuticals GmbH is responsible for coordinating the regulatory approval of the active ingredient, managing the production of D016, and maintaining worldwide logistics capabilities. A further location in Florida, USA, is dedicated to securing FDA approval.
OUR STRATEGY – WHERE SCIENCE MEETS MARKET SUCCESS
Pharmact combines years of research, preclinically proven efficacy, and a clearly scalable market strategy. Our proprietary enzyme D016 directly targets the causes of serious vascular diseases such as arteriosclerosis – in a global multi-billion-dollar market with enormous growth potential.
The unique combination of the properties of PH20 and HYAL-4 gives our active substance disruptive potential: entirely new therapeutic options for patient groups that have so far been inadequately treated. The leading international institute, Charles River Laboratories (USA), has confirmed its efficacy in meaningful preclinical models – a decisive milestone for us on the path to regulatory approval.
With a clearly defined clinical development plan – starting with high-risk patients suffering from familial hypercholesterolaemia and arteriosclerosis – and our fully integrated value chain from research through to distribution, we minimise development risks and ensure rapid production scaling. Strategic partnerships, strong patent protection, and targeted market positioning form the basis for sustainable returns.
For investors, this means access to a rare combination of raw material and active ingredient innovation with international scalability and above-average return potential. Become part of this development and invest in a technology that will redefine medical standards.
INVESTING IN THE HEALTH OF THE FUTURE
From the laboratory to life-changing therapy – Pharmact’s enzyme “D016” is redefining treatment for millions of people.
With our BELACT project, we are pursuing an innovative biotechnological therapeutic approach for the treatment of rare conditions such as familial hypercholesterolaemia, as well as other vascular diseases including arteriosclerosis – a widespread condition of enormous societal and economic significance.
Be part of the next chapter in medical innovation. As BELACT advances through Phases I–III, we invite partners to share in the growth of a patented therapy platform with worldwide scalability. From licensing to high-value M&A, your investment accelerates science, market impact, and long-term returns.
Click „Investor“ to get in touch.